tetano
Editor, Senior Moderator
Pharmacol Res. 2020 May 4:104882. doi: 10.1016/j.phrs.2020.104882. [Epub ahead of print]
The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence.
Zhang D[SUP]1[/SUP], Zhang B[SUP]2[/SUP], Lv JT[SUP]1[/SUP], Sa RN[SUP]3[/SUP], Zhang XM[SUP]1[/SUP], Lin ZJ[SUP]1[/SUP].
Author information
Abstract
The outbreak of emerging infectious pneumonia caused by 2019 Novel Coronavirus (2019-nCoV) has posed an enormous threat to public health, and traditional Chinese medicine (TCM) have made vast contribution to the prevention, treatment and rehabilitation of coronavirus disease 19 (COVID-19) among Chinese population. As an indispensable part of TCM, Chinese patent medicines (CPMs) are highly valued and critically acclaimed in their campaign to contain and tackle the epidemic, they can achieve considerable effects for both suspected cases under medical observation period, and confirmed individuals with serious underlying diseases or critical conditions. Given this, based on the Guideline on Diagnosis and Treatment of Coronavirus Disease 2019 in China, the present review summarized the basic information, clinical evidence and published literatures of recommended CPMs against COVID-19. The details were thoroughly introduced involving compositions, therapeutic effects, clinical indications, medication history of CPMs and the profiles of corresponding research. With regard to infected patients with different stages and syndrome, the preferable potentials and therapeutic mechanism of CPMs were addressed through the comprehensive collection of relevant literatures and on-going clinical trials. This study could provide an insight into clinical application and underlying mechanism of recommended CPMs against COVID-19, with the aim to share the Chinese experience in clinical practice and facilitate scientific development of TCM, especially CPMs in the fierce battle of COVID-19.
Copyright ? 2020. Published by Elsevier Ltd.
KEYWORDS:
COVID-19; Chinese patent medicines; current evidence; review
PMID:32380051DOI:10.1016/j.phrs.2020.104882
The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence.
Zhang D[SUP]1[/SUP], Zhang B[SUP]2[/SUP], Lv JT[SUP]1[/SUP], Sa RN[SUP]3[/SUP], Zhang XM[SUP]1[/SUP], Lin ZJ[SUP]1[/SUP].
Author information
Abstract
The outbreak of emerging infectious pneumonia caused by 2019 Novel Coronavirus (2019-nCoV) has posed an enormous threat to public health, and traditional Chinese medicine (TCM) have made vast contribution to the prevention, treatment and rehabilitation of coronavirus disease 19 (COVID-19) among Chinese population. As an indispensable part of TCM, Chinese patent medicines (CPMs) are highly valued and critically acclaimed in their campaign to contain and tackle the epidemic, they can achieve considerable effects for both suspected cases under medical observation period, and confirmed individuals with serious underlying diseases or critical conditions. Given this, based on the Guideline on Diagnosis and Treatment of Coronavirus Disease 2019 in China, the present review summarized the basic information, clinical evidence and published literatures of recommended CPMs against COVID-19. The details were thoroughly introduced involving compositions, therapeutic effects, clinical indications, medication history of CPMs and the profiles of corresponding research. With regard to infected patients with different stages and syndrome, the preferable potentials and therapeutic mechanism of CPMs were addressed through the comprehensive collection of relevant literatures and on-going clinical trials. This study could provide an insight into clinical application and underlying mechanism of recommended CPMs against COVID-19, with the aim to share the Chinese experience in clinical practice and facilitate scientific development of TCM, especially CPMs in the fierce battle of COVID-19.
Copyright ? 2020. Published by Elsevier Ltd.
KEYWORDS:
COVID-19; Chinese patent medicines; current evidence; review
PMID:32380051DOI:10.1016/j.phrs.2020.104882